Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:05 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 79,288 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age

NCT02186626
View directory record Official record
Conditions
West Nile Virus
Interventions
WN/DEN4Δ30 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Nov 3, 2026, 11:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Soy, Bone and Health in College Females

NCT00244478
View directory record Official record
Conditions
Osteoporosis, Obesity
Interventions
Soy Protein Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 19 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 2Phase 3 Interventional

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT03655678
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 3, 2026, 11:05 AM EST
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 2 Interventional

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

NCT00096525
View directory record Official record
Conditions
Kidney Cancer
Interventions
lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 1Phase 2 Interventional

12-step Facilitation for the Dually Diagnosed

NCT00583440
View directory record Official record
Conditions
Alcoholism, Diagnosis, Dual (Psychiatry)
Interventions
12-step facilitation, Treatment as usual
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Phase 1 Interventional

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

NCT01705340
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 3 Interventional Results available

A Study of PTC923 in Participants With Phenylketonuria

NCT05099640
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Phase 2 Interventional Results available

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

NCT03463889
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Nov 3, 2026, 11:05 AM EST
Completed No phase listed Observational

Biological Determinants of Peritoneal Dialysis

NCT02694068
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Peritoneal Equilibrium Test, 4 hour dwell of 2.5/4.25% dextrose solution
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years and older
Enrollment
4,865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Not applicable Interventional Results available

Effect of Fenugreek on Milk Production

NCT00851591
View directory record Official record
Conditions
Lactation
Interventions
fenugreek, Placebo (Psyllium)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Nov 3, 2026, 11:05 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 2Phase 3 Interventional Results available

Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

NCT01291160
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Epiflo, Moist Wound Therapy
Device · Other
Lead sponsor
Neogenix, LLC dba Ogenix
Industry
Eligibility
20 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Nov 3, 2026, 11:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Communicating Objective Risk for Personalized Decision Making About Mammography

NCT01686360
View directory record Official record
Conditions
Breast Cancer
Interventions
Decision Aid
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 49 Years · Female only
Enrollment
1,560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Daratumumab SC: daratumumab + rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 3, 2026, 11:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Eating Education for Latinos

NCT04724382
View directory record Official record
Conditions
Diet, Healthy, Diet Habit, Obesity, Blood Pressure, Psychological
Interventions
Culturally tailored healthy eating advice, Standard healthy eating advice
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
25 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Nov 3, 2026, 11:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Nov 3, 2026, 11:05 AM EST
Terminated Phase 2 Interventional

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

NCT02910882
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
Drug · Radiation
Lead sponsor
Scripps Health
Other
Eligibility
Up to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 1 Interventional

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

NCT00323323
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
CHOP, Alemtuzumab, Plasma Samples
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 3, 2026, 11:05 AM EST
Recruiting Phase 2 Interventional

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359
View directory record Official record
Conditions
IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
Interventions
ADX-038 Dose Level 2, ADX-038 Dose Level 1
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 11:05 AM EST
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

NCT01189279
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 64 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Nov 3, 2026, 11:05 AM EST